evalu
use
serum
aspergillu
pcr
assay
diagnosi
prognosi
invas
aspergillosi
studi
involv
patient
total
serum
sampl
fiftyon
patient
provenprob
aspergillosi
compar
galactomannan
gm
pcr
mycolog
analysi
pulmonari
sampl
neutropen
nonneutropen
patient
pcr
perform
serum
yield
sensit
specif
posit
predict
valu
neg
predict
valu
gm
index
yield
sensit
specif
posit
predict
valu
neg
predict
valu
inclus
pcr
european
organ
research
treatment
cancer
eortc
mycosi
studi
group
msg
mycolog
criteria
permit
reclassif
nine
case
possibl
probabl
aspergillosi
increas
sensit
combin
gm
index
serum
pcr
increas
detect
rate
invas
aspergillosi
sensit
pcr
systemat
neg
patient
noninvas
form
aspergillosi
name
aspergilloma
chronic
aspergillosi
remain
pcr
posit
period
day
treatment
relat
poor
outcom
day
result
also
indic
unlik
determin
gm
index
initi
fungu
load
determin
pcr
highli
predict
mortal
rate
latter
patient
copiesml
vs
patient
cutoff
p
therefor
pcr
appear
power
interest
tool
identif
patient
invas
aspergillosi
might
benefit
intens
care
invas
aspergillosi
ia
major
threat
immunocompromis
host
earli
diagnosi
initi
appropri
antifung
therapi
essenti
improv
prognosi
diseas
howev
diagnosi
ia
remain
difficult
current
frequent
base
set
host
clinic
mycolog
criteria
defin
jointli
european
organ
research
treatment
cancer
eortc
mycosi
studi
group
msg
eortcmsg
criteria
galactomannan
gm
assay
noninvas
mycolog
diagnost
method
current
avail
although
assay
interest
wide
use
lack
sensit
especi
nonneutropen
patient
also
may
influenc
use
certain
medic
devic
antibiot
lead
larg
number
falseposit
result
gm
detect
also
report
invas
fungal
diseas
due
aspergillu
moreov
present
mani
fungu
speci
therefor
specif
aspergillosi
tool
develop
improv
diagnosi
includ
particular
realtim
pcr
blood
sampl
detect
circul
aspergillu
dna
sever
studi
shown
potenti
interest
pcr
approach
lack
standard
yet
includ
eortc
msg
mycolog
criteria
recent
howev
panel
expert
argu
inclus
criteria
present
studi
aim
evalu
perform
inhous
fumigatu
realtim
pcr
assay
use
ml
volum
serum
diagnosi
ia
atrisk
patient
neutropen
nonneutropen
compar
pcr
result
gm
assay
determin
prognost
contribut
design
retrospect
singlecentr
analysi
perform
februari
octob
de
la
pari
franc
patient
risk
ia
routin
subject
monitor
serolog
assay
detect
gm
antigen
serolog
pcr
detect
fumigatu
dna
present
studi
focus
patient
provenprob
ia
accord
eortcmsg
criteria
extend
includ
addit
criteria
alcohol
liver
cirrhosi
long
stay
intens
care
unit
sever
acut
respiratori
distress
syndrom
host
factor
alreadi
report
gm
either
serum
bronchoalveolar
lavag
bal
use
mycolog
criterion
probabl
case
gm
determin
pcr
result
also
avail
patient
noninvas
aspergillosi
use
realtim
pcr
target
previous
describ
bp
segment
ribosom
rna
code
dna
primer
sequenc
ctcgca
tcctcggtccaggcag
probe
tgtcttatagccgaggg
tgcaatggg
tamra
dna
extract
perform
ml
serum
magna
pure
compact
larg
volum
kit
magna
pure
devic
roch
elut
volum
amplif
perform
fast
realtim
pcr
system
appli
biosystem
quantif
achiev
use
five
serial
tenfold
dilut
plasmid
pgemt
contain
target
final
pcr
result
express
number
copi
per
millilitr
serum
use
intern
control
assay
well
taqman
exogen
intern
posit
control
well
extract
control
albumin
gene
sampl
pcr
perform
duplic
singl
posit
well
consid
posit
result
gm
index
determin
enzym
immunoassay
biorad
accord
manufactur
recommend
result
consid
posit
two
determin
perform
two
differ
assay
sampl
show
index
serum
bal
test
perform
use
graphpad
prism
softwar
onlin
site
biostatgv
http
biostatgv
studi
period
gm
assay
fumigatu
pcr
perform
patient
fig
clinic
data
avail
patient
serum
sampl
diagnosi
proven
probabl
ia
made
respect
six
patient
accord
extend
eortcmsg
criteria
moreov
noninvas
form
aspergillosi
diagnos
patient
although
studi
focus
exhaust
identif
possibl
case
regist
diagnos
ia
base
host
factor
clinic
evalu
nine
patient
classifi
possibl
ia
accord
eortcmsg
criteria
patient
posit
serum
pcr
among
patient
proven
probabl
aspergillosi
femal
male
median
age
year
rang
year
twentytwo
patient
neutropen
absolut
neutrophil
count
time
diagnosi
underli
condit
haematopoiet
stem
cell
transplant
n
haematolog
malign
n
heart
transplant
n
liver
transplant
n
kidney
transplant
n
liverkidney
transplant
n
other
risk
factor
present
seven
patient
follow
sever
acut
respiratori
distress
syndrom
n
oncolog
diseas
n
alcohol
liver
cirrhosi
n
cardiogen
shock
n
multiorgan
failur
long
stay
intens
care
unit
n
perform
gm
index
mycolog
examin
respiratori
sampl
pcr
diagnosi
proven
probabl
aspergillosi
diagnosi
provenprob
ia
accord
extend
eortcmsg
criteria
n
made
patient
posit
gm
index
fig
pcr
posit
patient
includ
posit
gm
serum
four
posit
mycolog
analysi
respiratori
sampl
posit
gm
serum
posit
mycolog
analysi
respiratori
sampl
one
isol
posit
gm
bal
includ
five
neg
serum
gm
index
one
patient
posit
pcr
result
diagnosi
probabl
aspergillosi
base
posit
gm
index
bal
sampl
sensit
serum
gm
index
mycolog
examin
serum
pcr
confid
interv
ci
ci
ci
respect
note
sensit
gm
pcr
case
proven
aspergillosi
similar
patient
among
patient
diagnosi
clinic
form
aspergillosi
exclud
clinician
posit
gm
pcr
result
noninvas
form
aspergillosi
among
noninvas
aspergillosi
patient
ten
immunocompet
three
metastat
malign
two
solid
organ
transplant
one
alcohol
liver
cirrhosi
clinic
form
simpl
aspergilloma
n
colon
n
chronic
cavitari
aspergillosi
n
chronic
bronchiti
n
addit
clinic
condit
host
histori
radiolog
featur
patient
diagnos
support
mycolog
examin
n
presenc
antiaspergillu
antibodi
n
n
none
patient
posit
serum
gm
pcr
nine
patient
treat
ia
classifi
possibl
case
due
lack
eortcmsg
mycolog
criteria
seven
male
two
femal
six
patient
neutropen
five
haematolog
malign
one
haematopoiet
stem
cell
transplant
three
one
liver
transplant
one
kidney
transplant
one
sever
acut
respiratori
distress
syndrom
nine
patient
posit
pcr
result
thu
consid
pcr
mycolog
criterion
would
enabl
reclassif
nine
patient
possibl
probabl
ia
increas
number
patient
proven
probabl
ia
tabl
consid
patient
pcr
sensit
tend
better
neutropen
patient
nonneutropen
patient
differ
reach
statist
signific
p
power
test
p
insuffici
draw
conclus
pcr
specif
differ
two
group
gm
index
sensit
differ
two
group
specif
significantli
lower
neutropen
patient
compar
nonneutropen
patient
p
among
patient
ia
least
one
sampl
taken
initi
target
antifung
therapi
patient
sampl
taken
treatment
initi
except
five
patient
die
earli
time
diagnosi
patient
receiv
antifung
therapi
receiv
empir
therapi
caspofungin
receiv
target
antiaspergillu
therapi
voriconazol
amphotericin
b
among
patient
receiv
antifung
drug
pcr
gm
yield
similar
sensit
also
differ
accord
antifung
drug
provid
among
patient
without
antifung
therapi
sensit
pcr
gm
differ
statist
signific
p
compar
patient
receiv
antifung
therapi
statist
signific
differ
sensit
pcr
gm
realtim
pcr
allow
quantif
fungu
load
result
express
number
aspergillu
gene
copi
per
millilitr
serum
gm
result
present
index
interpret
quantit
consid
assess
variat
decreas
increas
pcr
gm
index
determin
abil
predict
treatment
efficaci
mortal
concern
respons
target
antifung
therapi
observ
earli
variat
pcr
result
fungu
load
decreas
quickli
initi
treatment
even
outcom
favour
moreov
increas
decreas
number
copi
first
week
relat
day
day
outcom
howev
patient
becom
pcr
neg
one
clear
initi
load
day
day
treatment
initi
aliv
day
n
remain
pcr
posit
period
poor
outcom
mortal
day
tabl
result
highli
signific
p
fisher
exact
test
pcr
result
day
also
predict
day
outcom
tabl
one
patient
clear
initi
load
consid
neg
clinic
microbiolog
infect
volum
number
june
initi
fungu
load
predict
outcom
also
assess
initi
fungu
load
predictor
outcom
receiv
oper
characterist
curv
evalu
fungu
load
marker
mortal
ia
indic
copiesml
cutoff
offer
effici
valu
fig
patient
pcr
result
strictli
copiesml
higher
probabl
surviv
day
diagnosi
n
surviv
compar
pcr
result
cutoff
n
surviv
median
surviv
day
fig
result
highli
statist
signific
p
log
rank
test
test
hazard
ratio
ci
ratio
similar
result
obtain
patient
consid
ie
includ
patient
neg
pcr
copiesml
group
differ
two
group
term
age
sex
ratio
underli
diseas
antifung
therapi
tabl
also
differ
concern
interv
sampl
start
target
antifung
therapi
comparison
among
patient
initi
posit
gm
patient
gm
effici
valu
appear
favour
outcom
other
although
differ
statist
signific
p
log
rank
test
fig
patient
initi
gm
n
surviv
appear
favour
outcom
other
n
surviv
differ
statist
signific
p
log
rank
mantelcox
test
hazard
ratio
ci
ratio
ci
confid
interv
gm
galactomannan
ia
invas
aspergillosi
roc
receiv
oper
characterist
consid
method
matur
enough
inclus
metaanalys
inde
demonstr
pcr
offer
sensit
rang
specif
rate
similar
attain
gm
assay
moreov
pcr
permit
use
qualiti
control
interlaboratori
check
provid
robust
quantif
assess
determin
gm
index
result
present
studi
add
evid
pcr
sensit
reach
specif
studi
pcr
appear
offer
interest
ppv
ie
patient
contrast
gm
index
highfals
posit
rate
particularli
neutropen
patient
led
poor
overal
ppv
pcr
gm
offer
interest
neg
predict
valu
pcr
sensit
neutropen
patient
nonneutropen
patient
differ
signific
p
increas
number
patient
could
lead
signific
result
nevertheless
studi
show
pcr
also
use
nonneutropen
patient
nonhaematolog
popul
solid
organ
transplant
recipi
previous
report
result
indic
perform
gm
determin
pcr
sampl
increas
sensit
koo
et
al
report
relat
gm
outcom
bergeron
et
al
report
patient
poor
outcom
day
initi
antifung
treatment
high
baselin
serum
gm
howev
found
nonstatist
signific
trend
gm
index
determin
outcom
nevertheless
bergeron
et
al
also
found
associ
outcom
aspergillu
dna
detect
work
support
initi
level
aspergillu
dna
highli
predict
mortal
rate
concern
result
specif
found
pcr
threshold
copiesml
could
discrimin
patient
low
threshold
high
probabl
mortal
pcr
thu
much
greater
discrimin
capac
determin
gm
index
result
could
use
identifi
patient
may
benefit
intens
care
design
clinic
studi
also
show
pcr
quantif
use
followup
predict
outcom
week
therapi
increas
decreas
number
copi
relev
assess
treatment
efficaci
outcom
howev
pcr
result
week
treatment
appear
relev
studi
patient
neg
pcr
add
one
patient
clear
initi
load
day
aliv
day
seven
still
aliv
day
vs
none
five
patient
remain
pcr
posit
work
initi
european
aspergillu
pcr
initi
white
et
al
clearli
demonstr
pcr
perform
plasma
give
better
result
pcr
perform
serum
consider
evid
chang
method
pcr
use
studi
specif
fumigatu
speci
thu
would
amplifi
genom
speci
flavu
niger
nidulan
may
explain
least
part
rel
lack
sensit
pcr
studi
nonfumigatu
speci
may
account
diseas
howev
retriev
caus
speci
case
strikingli
fumigatu
go
forward
util
pcr
ia
determin
cutoff
evalu
laboratori
specimen
cerebrospin
fluid
bal
aspergillu
dna
detect
serum
pcr
interest
tool
diagnosi
ia
neutropen
nonneutropen
patient
use
concomitantli
gm
index
atrisk
popul
moreov
pcr
allow
quantif
fungu
load
result
indic
threshold
copi
ml
power
discrimin
patient
low
threshold
high
probabl
mortal
therefor
initi
fungu
load
variat
fungu
load
treatment
determin
pcr
robust
predict
marker
mortal
may
use
identifi
patient
might
benefit
closer
attent
care
